Medicine makes great money for Novo Nordisk – beats expectations

Shareholders in Novo Nordisk will receive a nice dividend after the company presented its annual report on Wednesday. The pharmaceutical giant earned almost 2 billion DKK per week or just over 100 billion DKK in 2024.

“In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&D pipeline and on the expansion of our production capacity,” says CEO Lars Fruergaard Jørgensen. Photo: Novo Nordisk

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical company Novo Nordisk is shoveling in money.The total profit is 101 billion DKK. Revenue in 2024 was 290.4 billion DKK, both figures are slightly more than analysts had expected.“We are pleased with the performance in 2024, where 26% sales […]


Gain unlimited access to all of The Copenhagen Post

Our independent reporting can only be published with support from our readers.

Monthly subscription

119

DKK/month.

(Billed once a month)

Give us a try

6 month subscription

99

DKK/month.

(Billed twice a year)

Save 120 DKK

Yearly subscription

79

DKK/month.

(Billed once a year)

Save 480 DKK

Save with a company subscription?